key: cord-0811066-79xhb2bf
authors: Sargiacomo, Camillo; Sotgia, Federica; Lisanti, Michael P.
title: COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
date: 2020-03-30
journal: Aging (Albany NY)
DOI: 10.18632/aging.103001
sha: fd2755d592ea619049679894e4ef830fd0a15437
doc_id: 811066
cord_uid: 79xhb2bf

COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is a functional association between COVID-19 infection and the process of chronological aging. Two host receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention of COVID-19 disease.

AGING This specific association of COVID-19 fatality with advanced chronological age was directly validated by the CDC in the US population [2] and published in the Morbidity and Mortality Weekly Report (MMWR) on the 18 th of March, as follows: "This first preliminary description of outcomes among patients with COVID-19 in the United States indicates that fatality was highest in persons aged ≥85, ranging from 10% to 27%, followed by 3% to 11% among persons aged 65-84 years, 1% to 3% among persons aged 55-64 years, <1% among persons aged 20-54 years, and no fatalities among persons aged ≤19 years".

Two host receptors have been proposed for COVID-19. One is CD26 [3] and the other is ACE-2 (angiotensinconverting enzyme 2) [4] . Interestingly, both CD26 and the angiotensin system show associations with senescence. For example, ACE-2 is a known inhibitor of cell proliferation and the angiotensin system is upregulated in both premature and replicative senescence [5, 6] . Remarkably, CD26 is known to be a bonafide cell surface marker of senescent cells [7] . Similarly, myofibroblasts (which are considered to be senescent and pro-fibrotic cells) also over-express CD26 and ACE-2 [8, 9] . Senescent cells produce large amounts of inflammatory cytokines, as a result of the senescence-associated secretory phenotype (SASP), including IL-6.

Interestingly, the host receptor for MERS-CoV, a highly-related corona virus, is CD26, also known as dipeptidyl-peptidase IV (DPP4) [10] [11] [12] . Genetic evidence, including functional studies of existing CD26 human polymorphisms and humanized CD26 transgenic mouse animal models, has directly shown that CD26 is the functional host receptor for MERS-CoV, which is specifically required for host cell attachment, entry and, therefore, productive host cell infections, as well as species restrictions [10] [11] [12] Moreover, recent structural studies predict that the COVID-19 spike glycoproteins also directly interact with host cell CD26 [3] .

Thus, one hypothesis is that the COVID-19 virus significantly increases mortality in patients with advanced chronological age, because these patients have an increased number of senescent lung cells, which are the host target for COVID-19 viral infection. Interestingly, senescent cells also show an increased propensity for enhanced protein synthesis, which is required to produce SASP inflammatory mediators, which would make senescent cells an ideal host target for efficient viral replication. Therefore, it would be predicted that senolytic drugs could have a beneficial effect for the treatment and/or prevention of COVID-19 disease. Is there any evidence to support this attractive hypothesis?

Recently, a clinical trial was conducted using COVID-19 positive hospitalized patients, which assessed COVID-19 virus production in response to treatment with two FDA-approved drugs, namely Hydroxychloroquine (Plaquenil) and Azithromycin (Z-PAC) [13] . Hydroxy-chloroquine alone, at the standard dosages, was surprisingly effective in reducing COVID-19 viral production. However, the combination of Hydroxy-chloroquine and Azithromycin appeared to be even more effective. The mechanism(s) by which this drug combination halts COVID-19 virus production remains unknown.

Chloroquine and its derivatives, such as Hydroxychloroquine, alkalinize the pH in lysosomes, which accumulate in large numbers in senescent cells. This Chloroquine-induced alkalinization functionally prevents the induction and accumulation of one of the most widely-recognized markers of senescence, known as beta-galactosidase (Beta-Gal), a lysosomal enzyme [14] . Hydroxy-chloroquine is also used clinically for the treatment of chronic inflammatory diseases, such as Sjögren's syndrome, and it effectively reduces the salivary and serum levels of IL-6, a key component of the SASP [15] .

Azithromycin also has a key relationship with senescence [16] . Recent studies have shown that Azithromycin, and the closely related drug Roxithromycin, both act as senolytic drugs that can target and selectively remove senescent cells, with an efficiency of nearly 97% [16] . Interestingly, in patients with Cystic Fibrosis, Azithromycin is known to have an anti-fibrotic effect, which significantly extends their lifespan, by targeting myofibroblast cells (Discussed in Ref [16] ). Cystic Fibrosis patients normally die from lung inflammation and fibrosis, resulting in lung stiffening and an inability to respire. Fibrosis is also known to be an age-related phenomenon, associated with increased numbers of myofibroblasts (senescent cells), which increases with chronological age. Azithromycin functionally acts as an anti-inflammatory drug and reduces SASP mediators, such as IL-1beta and IL-6 [17, 18] . This may be due to Azithromycin's high senolytic activity and/or inhibition of protein synthesis.

Interestingly, Azithromycin also inhibits the replication of other viruses, such as Zika and Ebola [19] [20] [21] . If this AGING inhibitory activity reflects Azithromycin's ability to inhibit protein synthesis, then other inhibitors of protein synthesis, such as Rapamycin, should be considered as well (see Supplementary Figure 1 ). Consistent with this hypothesis, Rapamycin has been shown to potently inhibit HIV-1 replication [22] . Moreover, Rapamycin shows key anti-aging properties and prevents the onset of senescence [23] [24] [25] .

Similarly, Doxycycline inhibits mammalian cell protein synthesis as an off-target side effect [26] , effectively blocks replication of Dengue virus [27] , reduces IL-6 serum levels during viral infection [28] and behaves as an anti-aging drug [29] . Therefore, Doxycycline could provide another inexpensive, but very attractive, option for the treatment or prevention of COVID-19 infection.

Finally, a recent study, using supercomputer-based in silico drug-docking to the COVID-19 viral spike protein identified Quercetin as a potential binding partner, to reduce virus-host interactions, with ACE-2 [30] . Quercetin has also been identified as a dietary supplement with senolytic properties [31] .

Therefore, we propose that the clinical relationship between advanced chronological age and COVID-19 mortality may suggest the use of senolytic or anti-aging drugs in COVID-19 disease prevention (Figure 1 ). Of course, clinical trials will be necessary to test this attractive, but speculative, hypothesis experimentally.

Fortunately, several promising senolytic and other antiaging drugs are already FDA-approved for other disease indications. This approach can significantly accelerate their clinical evaluation through drug repurposing, as they have already been evaluated for their clinical safety, in Phase I trials. As such, these FDA-approved drugs can directly enter into Phase II clinical trials, to test their potential efficacy against COVID-19. Alternatively, in the United States, FDA-approved drugs can be medically-prescribed for an "off-label" use, at the discretion of the practicing physician.

Interestingly, SARS-CoV, a close relative of COVID-19 (SARS-CoV-2), also shows increased susceptibility in patients with advanced chronological age, which has been recapitulated in a mouse animal model of disease pathogenesis [32, 33] . Briefly, in young mice (4-8 weeks-old), the SARS-CoV infection is cleared very rapidly, which is accompanied by mild pneumonitis, without the activation of cytokine production. In contrast, in older mice (12-14-months-old), productive infection with SARS-CoV led to a more severe interstitial pneumonitis, with alveolar damage, significant fibrosis and scarring, as well as severe activation of cytokine production, including TNF-α, IL-6, CCL-2, CCL-3, CXCL-10, and IFN-γ [32, 33] . This latter mouse model more closely resembles the SARS-CoV disease phenotype, observed in patients with advanced chronological age. Therefore, such a mouse model would also be useful for testing the efficacy of new therapies, specifically targeting the senescent cell Figure 1 . What is the relationship between COVID-19 and advanced chronological age? Here, we suggest that the COVID-19 corona virus preferentially targets senescent lung cells, resulting in increased morbidity and mortality in the aging population. One possible solution for prevention/treatment would be the use of senolytics or other anti-aging drugs. Testing this hypothesis will require the necessary clinical trials, with a focus on drug repurposing. AGING population and SASP, for the repurposing of these FDA-approved anti-aging drugs.

This perspective is intended for a professional audience, to stimulate new ideas and to aid the global efforts to develop effective treatments for COVID-19 disease. This article does not represent medical advice or recommendations to patients. The media should exercise caution and seek expert medical advice for interpretation, when referring to this article.

While this Perspective was being reviewed, another clinical trial was published online, confirming the efficacy of Hydroxy-chloroquine and Azithromycin, for treating COVID-19 patients, in a larger cohort of 80 patients. See the following article:

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19) -United States

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Upregulation of angiotensin converting enzyme 2 by shear stress reduced inflammation and proliferation in vascular endothelial cells

The Redox-sensitive Induction of the Local Angiotensin System Promotes Both Premature and Replicative Endothelial Senescence: Preventive Effect of a Standardized Crataegus Extract

Identification of senescent cell surface targetable protein DPP4

Functional angiotensin-converting enzyme 2 is expressed in AGING human cardiac myofibroblasts

Elevated CD26 Expression by Skin Fibroblasts Distinguishes a Profibrotic Phenotype Involved in Scar Formation Compared to Gingival Fibroblasts

Polymorphisms in dipeptidyl peptidase 4 reduce host cell entry of Middle East respiratory syndrome coronavirus

Middle East respiratory syndrome-coronavirus infection into established hDDP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis

Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells

Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers

Azithromycin and Roxithromycin define a new family of "senolytic" drugs that target senescent human fibroblasts

Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model

Azithromycin attenuates acute radiation-induced lung injury in mice

Zika virus cell tropism in the developing human brain and inhibition by azithromycin

Azithromycin Inhibits the Replication of Zika Virus

Evaluation of Ebola Virus Inhibitors for Drug Repurposing

The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication

Rapamycin for longevity: opinion article

Rapamycin, proliferation and geroconversion to senescence

Rapamycin decelerates cellular senescence

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: mito-stemness and ribostemness features

Inhibitory effect of doxycycline against dengue virus replication in vitro

Dengue Patients Treated with Doxycycline Showed Lower Mortality Associated to a Reduction in IL-6 and TNF Levels

Mitonuclear protein imbalance as a conserved longevity mechanism

Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface

Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice

Genomic analysis reveals age-dependent innate immune responses to severe acute respiratory syndrome coronavirus

Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection

We are grateful to Rumana Rafiq for her kind and dedicated assistance in keeping the Translational Medicine Laboratory at the University of Salford running very smoothly. We would like to thank the Foxpoint Foundation (Canada) and the Healthy Life Foundation (UK) for their philanthropic donations towards new equipment and infrastructure in the Translational Medicine Laboratory at the University of Salford.

The authors have no conflicts of interest to declare.

The Lisanti/Sotgia Laboratory is supported by research grant funding, provided by Lunella Biotech, Inc.

Supplementary and Rapamycin are all FDA-approved drugs that behave as inhibitors of protein synthesis and experimentally have been shown to reduce inflammation and viral replication. Mechanistically, this is because cytokines and viruses are both made of proteins. Both use the cellular ribosomes for protein translation. Inhibiting virus production should help to clinically reduce viral transmission to other patients.